Plexium, Inc.

Plexium, Inc. is a privately held biotechnology company headquartered in San Diego, California, focused on the discovery and development of targeted protein degradation (TPD) therapeutics. The company describes itself as a next-generation TPD company and emphasizes the rational design of monovalent direct degraders and molecular glues — small-molecule compounds intended to become first-in-class or best-in-class treatments for high unmet medical needs. Plexium's discovery efforts are powered by its proprietary DELTA Discovery™ platform, which the company describes as an AI-integrated phenotypic and functional drug discovery engine. According to the company, this platform has supported the advancement of multiple clinical-stage protein degraders, and Plexium leverages a suite of enabling technologies intended to expand the "druggable" target space for TPD and beyond. The company is led by Chief Executive Officer Serge Messerlian, M.Sc., M.B.A., alongside a leadership team that includes Chief Medical Officer Jorge F. DiMartino, M.D., Ph.D.; Chief Financial Officer Stephen Mullennix; and senior vice presidents in chemistry, CMC, and biology. Mike Grey serves as Executive Chairman. Plexium's board and investor representation includes individuals affiliated with The Column Group, TCG X, aMoon, BVF Partners L.P., Pivotal Bioventure Partners, and DCVC Bio. Plexium operates in the highly competitive and rapidly evolving field of targeted protein degradation, where companies pursue small-molecule approaches to induce the selective elimination of disease-causing proteins. Its pipeline is described as targeting high unmet medical needs, with a focus on advancing clinical-stage protein degraders.

Plexium, Inc. is a biotechnology company based in San Diego, California, focused on targeted protein degradation (TPD). The company has positioned itself as a next-generation TPD company, emphasizing the rational design and discovery of monovalent direct degraders and molecular glues. Its small-molecule compounds are being developed as potential first-in-class and best-in-class treatments for high unmet medical needs. The company's discovery efforts are centered on its proprietary DELTA Discovery™ platform, which it describes as an AI-integrated phenotypic and functional drug discovery engine. According to Plexium, this platform has supported the advancement of multiple clinical-stage protein degraders, and the company leverages a suite of enabling technologies intended to expand the "druggable" target space for TPD and beyond. Plexium is led by CEO Serge Messerlian, with Mike Grey serving as Executive Chairman. Its leadership team includes Chief Medical Officer Jorge F. DiMartino, Chief Financial Officer Stephen Mullennix, and senior vice presidents overseeing chemistry, CMC, and biology. The company's board and investor base include representatives from The Column Group, TCG X, aMoon, BVF Partners L.P., Pivotal Bioventure Partners, and DCVC Bio.

Next-generation targeted protein degradation company focused on rationally designed monovalent direct degraders and molecular glues for high unmet medical needs.

• DELTA Discovery™ platform

  Proprietary AI-integrated phenotypic and functional drug discovery engine.

• Monovalent Direct Degraders

  Small molecule compounds designed to degrade disease-causing proteins.

• Molecular Glues

  Small molecule compounds that induce protein-protein interactions to degrade targets.

1. 1Plexium, Inc. • Delivering Transformative Precision Medicinesplexium.com
2. 2Plexium, Inc. - Wikidatawikidata.org
3. 3Protein-degrading Plexium debuts with $28M to attack cancer, neurodegenerative diseasefiercebiotech.com